Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its second quarter 2021 financial results on August 5, 2021, before the U.S. market opens. A conference call will be held at 8:30 a.m. ET to discuss financial and operational results. Xeris specializes in ready-to-use injectable formulations, with its proprietary technologies such as XeriSol™ and XeriJect™, aimed at simplifying administration and enhancing stability. The company's first commercial product is Gvoke®. Investors can register for the call and access a replay later.
- Xeris has developed innovative formulation technologies, XeriSol™ and XeriJect™, which enhance the ease of use and stability of injectable therapies.
- The company’s first commercial product, Gvoke®, addresses a significant market need.
- None.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that the Company will release its second quarter 2021 financial results before the open of the U.S. financial markets on Thursday, August 5, 2021. Management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s financial and operational results.
To pre-register for the conference call please use this link: https://www.incommglobalevents.com/registration/q4inc/8310/xeris-pharmaceuticals-second-quarter-financial-results/. After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, August 19, 2021 at (929) 458-6194 (US), 0204 525 0658 (UK) or +44 204 525 0658 (all other locations) Access Code: 743899.
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005147/en/
FAQ
When will Xeris Pharmaceuticals release its second quarter 2021 financial results?
What time is the conference call for Xeris Pharmaceuticals' financial results?
How can I register for the Xeris Pharmaceuticals conference call?
What is the stock symbol for Xeris Pharmaceuticals?
